Trinity Biotech PLC (NASDAQ:TRIB) Short Interest Update

Trinity Biotech PLC (NASDAQ:TRIB) was the recipient of a significant drop in short interest during the month of April. As of April 30th, there was short interest totaling 233,333 shares, a drop of 42.1% from the April 15th total of 402,865 shares. Approximately 7.1% of the company’s stock are sold short. Based on an average daily volume of 66,902 shares, the short-interest ratio is currently 3.5 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings cut shares of Trinity Biotech from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 8th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Reduce”.

Institutional Trading of Trinity Biotech

Institutional investors and hedge funds have recently made changes to their positions in the stock. Citadel Advisors LLC increased its stake in shares of Trinity Biotech by 196.1% in the third quarter. Citadel Advisors LLC now owns 39,384 shares of the company’s stock worth $41,000 after purchasing an additional 26,084 shares during the period. Williams & Novak LLC increased its stake in shares of Trinity Biotech by 677.5% in the fourth quarter. Williams & Novak LLC now owns 93,300 shares of the company’s stock worth $74,000 after purchasing an additional 81,300 shares during the period. Yorkville Advisors Global LP bought a new position in Trinity Biotech during the first quarter worth $122,000. Hunter Associates Investment Management LLC increased its position in Trinity Biotech by 8.1% during the fourth quarter. Hunter Associates Investment Management LLC now owns 526,610 shares of the company’s stock worth $417,000 after acquiring an additional 39,500 shares during the period. Finally, Perceptive Advisors LLC bought a new position in Trinity Biotech during the second quarter worth $1,164,000. Institutional investors and hedge funds own 78.97% of the company’s stock.

Trinity Biotech Stock Up 3.2%

Shares of NASDAQ:TRIB traded up $0.02 on Monday, reaching $0.59. The company had a trading volume of 294,915 shares, compared to its average volume of 207,606. Trinity Biotech has a twelve month low of $0.50 and a twelve month high of $3.44. The stock has a 50-day moving average price of $0.65 and a 200 day moving average price of $0.79. The stock has a market capitalization of $2.13 million and a P/E ratio of -0.06.

About Trinity Biotech

Trinity Biotech plc is a global diagnostic healthcare company headquartered in Bray, Ireland. The firm specializes in the development, manufacture and marketing of in vitro diagnostic products aimed at the detection and management of chronic and infectious diseases. Its offerings are designed to deliver timely and accurate results for a range of healthcare settings, from central laboratories to point?of?care environments.

The company’s product portfolio includes a comprehensive array of assays and instrumentation.